Streptococcus salivarius bacteremia and spontaneous bacterial peritonitis in liver transplantation candidates

Liver Transplantation

Volumn 13, Issue 11, 2007, Pages 1582-1588

  Gautam, Manjushree ^a   Chopra, Kapil B ^a   Douglas, David D ^a   Stewart, Rebecca A ^a   Kusne, Shimon ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMMONIA; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; CEFALEXIN; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CREATININE; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; ASCITES; ASCITES FLUID LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BACTERIAL PERITONITIS; BACTERIUM IDENTIFICATION; BLOOD CULTURE; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; FEMALE; FEVER; HUMAN; LEUKOCYTOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MEDICAL RECORD REVIEW; MORTALITY; PARACENTESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX RATIO; STREPTOCOCCUS INFECTION; STREPTOCOCCUS SALIVARIUS;

ADULT; AGED; BACTEREMIA; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PERITONITIS; RETROSPECTIVE STUDIES; STREPTOCOCCAL INFECTIONS;

EID: 36448933139     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21277     Document Type: Article

References (41)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353-358.
2. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001;33:41-48.
3. Potter BJ, Trueman AM, Jones EA. Serum complement in chronic liver disease. Gut 1973; 14:451-456.
4. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53-58.
5. DeMeo AN, Andersen BR. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med 1972;286:735-740.
6. Garcia-Gonzalez M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis. Gastroenterology 1993;105:527-531.
7. Akalin HE, Laleli Y, Telatar H. Serum bactericidal and opsonic activities in patients with non-alcoholic cirrhosis. Q J Med 1985;56:431-437.
8. Kuo CH, Changchien CS, Yang CY, Sheen IS, Liaw YF. Bacteremia in patients with cirrhosis of the liver. Liver 1991; 11:334-339.
9. Thulstrup AM, Sorensen HT, Schonheyder HC, Moller JK, Tage-Jensen U. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis, Clin Infect Dis 2000;31:1357-1361.
10. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 1994;38:340-344.
11. Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002;15:613-630.
12. Whiley RA, Beighton D. Current classification of the oral streptococci. Oral Microbiol Immunol 1998;13:195-216.
13. Corredoira JC, Alonso MP, Garcia JF, Casariego E, Coira A, Rodriguez A, et al. Clinical characteristics and significance of Streptococcus salivarius bacteremia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur J Clin Microbiol Infect Dis 2005;24:250-245.
14. Heidemann DG, Dunn SP, Haimann M. Streptococcus salivarius endophthalmitis from contaminated donor cornea after keratoplasty. Am J Ophthalmol 1989; 107:429-430.
15. Longman LP, Pearce PK, McGowan P, Hardy P, Martin MV. Antibiotic-resistant oral streptococci in dental patients susceptible to infective endocarditis. J Med Microbiol 1991;34:33-37.
16. Wisplinghoff H, Reinert RR, Cornely O, Seifert H. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol 1999;37:1876-1880.
17. Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2006;44:160-165.
18. Yaniv LG, Potasman I. Iatrogenic meningitis: an increasing role for resistant viridans streptococci? Case report and review of the last 20 years. Scand J Infect Dis 2000; 32:693-696.
19. Idigoras P, Valiente A, Iglesias L, Trieu-Cout P, Poyart C. Meningitis due to Streptococcus salivarius. J Clin Microbiol 2001;39:3017.
20. Peterson MC. Spontaneous bacterial peritonitis from Streptococcus salivarius in a compromised host. J Infect 2002;45:197-198.
21. Redondo Cerezo E, Morillas Arino J, Gomez Ruiz CJ, Garcia-Cano Lizcano J, Perez Vigara G, Perez Garcia JI, et al. [Spontaneous bacterial peritonitis due to Streptococcus salivarius in cirrhotic man.] Gastroenterol Hepatol 2004; 27:433-434. [Spanish]
22. Carley NH. Streptococcus salivarius bacteremia and meningitis following upper gastrointestinal endoscopy and cauterization for gastric bleeding. Clin Infect Dis 1992; 14: 947-948.
23. Barnett JL, Elta G. Bacterial peritonitis following endoscopic variceal sclerotherapy. Gastrointest Endosc 1987; 33:316-317.
24. Lin OS, Wu SS, Chen YY, Soon MS. Bacterial peritonitis after elective endoscopic variceal ligation: a prospective study. Am J Gastroenterol 2000;95:214-217.
25. Kiddy K, Brown PP, Michael J, Adu D. Peritonitis due to Streptococcus viridans in patients receiving continuous ambulatory peritoneal dialysis. Br Med J 1985:290:969-970.
26. Smith A, Jackson MS, Kennedy H. Antimicrobial susceptibility of viridans group streptococcal blood isolates to eight antimicrobial agents. Scand J Infect Dis 2004;36: 259-263.
27. Bert F, Noussair L, Lambert-Zechovsky N, Valla D. Viridans group streptococci: an underestimated cause of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Eur J Gastroenterol Hepatol 2005; 17:929-933.
28. Bert F, Andreu. M, Durand F, Degos F, Galdbart JO, Moreau R, et al. Nosocomial and community-acquired spontaneous bacterial peritonitis: comparative microbiology and therapeutic implications. Eur J Clin Microbiol Infect Dis 2003;22:10-15.
29. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-148.
30. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990;12: 716-724.
31. Llovet JM, Rodriguez-Iglesias P, Moitinho E, Planas R, Bataller R, Navasa M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis undergoing selective intestinal decontamination: a retrospective study of 229 spontaneous bacterial peritonitis episodes. J Hepatol 1997;26: 88-95.
32. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimendritis AJ. Increasing frequency of gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int 2005;25:57-61.
33. Bauer TM, Follo A, Navasa M, Vila J, Planas R, Clemente G, et al. Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence. Dig Dis Sci 2002;47:1356-1361.
34. Rolachon A, Cordier L, Bacq Y, Nousbaum JB, Franza A, Paris JC, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995;22:1171-1174.
35. Dickema DJ, Beach ML, Pfaller MA, Jones RN. Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. Clin Microbiol Infect 2001;7: 152-157.
36. De Pauw BE, Donnelly JP, De Witte T, Novakova IR, Schattenberg A. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrowtransplantrecipients. BoneMarrowTranspl 1990;5: 179-182.
37. Persson L, Vikerfors T, Sjoberg L, Engervall P, Tidefelt U. Increased incidence of bacteraemia due to viridans streptococci in an unselected population of patients with acute myeloid leukaemia. Scand J Infect Dis 2000: 32:615-621.
38. Donnelly JP, Dompeling EC, Meis JF, de Pauw BE. Bacteremia due to oral viridans streptococci in neutropenic patients with cancer: cytostatics are a more important risk factor than antibacterial prophylaxis. Clin Infect Dis 1995;20:469-470.
39. Tankovic J, Perichon B, Duval J, Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother 1996;40:2505-2510.
40. Greenberg RN, Kennedy DJ, Reilly PM, Luppen KL, Weinandt WJ, Bollinger MR, et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob Agents Chemother 1987;31:151-155.
41. Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005;24:832-838.